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Background: Functional comparative genomic analysis of the cellular immunological effects of different anti-
inflammatory phytocompounds is considered as a helpful approach to distinguish the complex and specific
bioactivities of candidate phytomedicines. Using LPS-stimulated THP-1 monocytes, we characterize here the
immunomodulatory activities of three single phytocompounds (emodin, shikonin, and cytopiloyne) and a defined
phytocompound mixture extracted from Echinacea plant (BF/S+L/Ep) by focused DNA microarray analysis of
selected immune-related genes.
Results: Shikonin and emodin significantly inhibited the early expression (within 0.5 h) of approximately 50 genes,
notably cytokines TNF-a, IL-1b and IL-4, chemokines CCL4 and CCL8, and inflammatory modulators NFATC3 and
PTGS2. In contrast, neither cytopiloyne nor BF/S+L/Ep inhibited the early expression of these 50 genes, but rather
inhibited most late-stage expression (~12 h) of another immune gene subset. TRANSPATH database key node
analysis identified the extracellular signal-regulated kinase (ERK) 1/2 activation pathway as the putative target of BF/
S+L/Ep and cytopiloyne. Western blot confirmed that delayed inactivation of the ERK pathway was indeed
demonstrable for these two preparations during the mid-stage (1 to 4 h) of LPS stimulation. We further identified
ubiquitin pathway regulators, E6-AP and Rad23A, as possible key regulators for emodin and shikonin, respectively.
Conclusion: The current focused DNA microarray approach rapidly identified important subgenomic differences in
the pattern of immune cell-related gene expression in response to specific anti-inflammatory phytocompounds.
These molecular targets and deduced networks may be employed as a guide for classifying, monitoring and
manipulating the molecular and immunological specificities of different anti-inflammatory phytocompounds in key
immune cell systems and for potential pharmacological application.
Background
Inflammation is the result of a cascade of physiological
and immunological reactions that aim to localize toxic
materials, fight pathogens and prevent tissue injury [1].
The inflammatory response consists of the sequential
release of mediators including inflammatory cytokines
and the recruitment of circulating leukocytes that
become activated at the inflammatory site and release
further mediators. In most cases, macrophage activation
constitutes the key orchestration and regulation event of
the inflammatory response [2].
Analysis of the kinetics of cytokine production during
the inflammatory response reveals that macrophage acti-
vation is the product of an underlying process that
impacts the genome within minutes and continues for
several hours. The transcriptional regulation of gene
expression is the mechanistic foundation of macrophage
activation [3-5]. At the onset (~0.5 h) and in the early
stages (within the first 2 h) of an inflammatory response,
NF-B, signal transducer and activator of transcription
(STAT), activator protein-1 (AP-1), and CCAAT enhan-
cer-binding protein (CEBP) control macrophage gene
expression [5,6]. A secondary response or mid-term
stage commences around 4 h, which primes the immune
system for the resolution, and there is a final late stage
response around 12 h after stimulus [7]. The interplay
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any medium, provided the original work is properly cited.of these three stages thus determines the outcome of the
specific and/or the overall inflammatory responses [5,8].
Detailed and mechanistic information concerning the
integration of the systems involved in these events is
useful not only for studies of immune-cell signaling
mechanisms but also for the development of remedies
(e.g., phytomedicines) to control excessive inflammation.
We hypothesized at the outset of this study that differ-
ent phytochemicals with reputed anti-inflammatory
activities may exhibit distinctive patterns of effects and
kinetics as they intervene in specific steps in the inflam-
matory cascade, and that such phytochemicals may thus
be subgrouped on those grounds, at the pharmacoge-
nomic level, for systematic mechanism studies or thera-
peutic applications.
The apparently integrated and programmed patterns
of gene expression regulating the various steps of an
inflammatory response make them a desirable target
system for studying functional genomics of innate
immunity. Currently, little comparative studies on the
anti-inflammatory activities of phytocompounds/herbal
extracts are available. Many phytocompounds are
believed to be immunomodulatory, we and others have
recently demonstrated such activities for a series of anti-
inflammatory phytocompounds including shikonin, an
inhibitor of TNF-a mRNA maturation [9] or transcrip-
tion [6], and emodin, which represses the inflammatory
response [10,11]. Another unique immuno-modulatory
compound, cytopiloyne, recently isolated from the
Asteraceae plant, Bidens pilosa [12], has also been
reported to decrease the symptoms of autoimmune dis-
ease in mouse type I diabetes [13]. We have observed
that both emodin and cytopiloyne can effectively modu-
late human dendritic cell function (unpublished results).
In addition to these pure phytocompounds, we also
reported earlier that a stem and leaf extract of Echina-
cea purpurea is anti-inflammatory in dendritic cells [14],
which suggests that some complex herbal preparations
may affect a spectrum of immune cell types during
inflammation.
An appropriate model system to study macrophage
activation is to investigate the response to lipopolysac-
charide (LPS) challenge in THP-1 cells, an immortalized
human monocyte/macrophage cell line that closely
resembles PBMC-derived macrophages [3,15-17]. LPS, a
molecular correlate of bacterial infection, binds directly
to Toll-like receptor 4 to trigger multiple signaling cas-
cades including those mediated through NF-B and the
Janus N-terminal kinase (JNK) and p38 kinase pathways
[18]. LPS elicits the expression of multiple macrophage
pro- and anti-inflammatory cytokines, and the resulting
effects may be protective or deleterious. Therefore, the
LPS-induced THP-1 cells provide a good inflammatory
model system that can reflect macrophage activation
induced by gram (-) bacteria and/or the related acute-
inflammation responses and sepsis [3]. The activation of
particular genes in these inflammatory response path-
ways is particularly amenable to study by functional
genomic approaches such as focused DNA microarray,
which uses an array of a limiteds u b s e to fg e n e s[ 3 , 1 9 ] .
Here, we demonstrated the utility of this approach in
characterization of the effects of different types of phy-
tocompounds on monocyte gene expression patterns.
Our findings also led us to hypothesize a number of
master switch molecules in these immune cells that can
respond differentially, at the signaling network level, to
distinct groups of candidate phytomedicines.
Results
Determination of test phytocompound cytotoxicity in
THP-1 cells
The immune modulatory effects of known anti-inflam-
matory phytocompounds and extracts were examined in
the human monocytic cell line THP-1. The cytotoxicity
of the test phytocompounds (shikonin, emodin, cytopi-
loyne and BF/S+L/Ep) was determined by MTT assay
following culture with various concentrations of the
compounds for 48 h (Figure 1). The highest concentra-
tions that led to no significant decrease in cell viability
(shikonin 0.5 μM, emodin 10 μM, cytopiloyne 20 μM,
and BF/S+L/Ep 100 μg/ml) were used in subsequent
experiments. Three phytochemicals (shikonin, emodin
and cytopiloyne) were isolated, obtained, and tested as
single, structurally known chemical compounds. Each of
these compounds has been previously shown to modu-
late certain immunological bioactivities [9-13,20]. Shiko-
nin is the active compound identified from a traditional
medicinal herb, Lithospermum erythrorhizon. Emodin is
an active compound presents in Rheum officinale. Cyto-
piloyne is an active compound isolated from the plant
Bidens pilosa. BF/S+L/Ep was named as the butanol par-
titioned fraction (BF) of the stem + leaf (S+L) tissue
extracts of the E. purpurea (Ep) plant. We have pre-
viously shown that this fraction may confer an immune-
modulatory effect in human dendritic cells [14,20].
Effect of phytocompounds on LPS-induced gene
expression
To determine the effects of test phytocompounds/
extracts on the LPS-induced inflammatory response in
THP-1 cells, we compared the gene expression profiles of
cells treated with LPS only and cells co-treated with LPS
and test phytocompounds at different time points. Total
RNA was collected at the indicated time points for
focused microarray analysis as described previously [14].
In LPS-stimulated THP-1 cells, 35 genes were either
up- or down-regulated (data not shown) more than
threefold compared to untreated cells (i.e., expression of
Chiu et al. BMC Genomics 2010, 11:513
http://www.biomedcentral.com/1471-2164/11/513
Page 2 of 18these genes increased to more than 300% of normal
expression, or decreased to less than 33% of normal
expression levels). Two anti-inflammatory compounds,
shikonin and emodin, inhibited the early LPS-induced
threefold increase of pro-inflammatory gene expression,
but cytopiloyne and BF/S+L/Ep did not show similar
inhibitory effects (Figure 2B) at the early stage of inflam-
matory response. Shikonin significantly inhibited the
expression of several genes (Table 1), including genes
for cytokines (TNF-a,I L - 1 b and IL-4), chemotaxis and
cell migration genes (CCL4 and CCL8) and inflamma-
tory response genes (NFATC3 and PTGS2). Emodin sig-
nificantly inhibited the increase in expression of several
common genes, including cytokines (IL-1b and IL-4),
and inflammatory response genes (NFATC3 and
PTGS2) within 0.5 h of exposure (Table 1).
At 4 h after exposure, both cytopiloyne and BF/S+L/
Ep treatments up-regulated the expression of cytokines
(CSF1, IL5 and TNFSF14) and cell-migration related
genes (including ITGAX and MADCAM1) (Table 2). At
the late stage of the LPS-induced inflammatory response
(12 h after exposure), BF/S+L/Ep significantly inhibited
(more than threefold decrease in expression ratio) sev-
eral inflammation response genes (GATA3, NFATC3,
PTGS2), cytokines (including IL-4), and chemotaxis and
cell adhesion genes (such as CCR2, CCR3, CXCR4 and
ITGA2) (Table 3).
Comparison of gene expression patterns among four
different treatments
For gene clustering analyses, we first applied the hier-
archical clustering method using the UPGMA
(unweighted average) program. The gene expression pat-
terns, as shown in the heat map in Figure 2A were then
arranged to compare the similarities and differences
between the experimental groups. While shikonin and
Figure 1 Determining the non-toxic concentrations of test phytocompounds in THP-1 cells. The highest non-toxic concentrations of test
phytocompounds (shikonin, emodin, cytopiloyne and BF/S+L/Ep extract) were determined by MTT assay. THP-1 cells were cultured with
different phytocompounds for 48 h. Assays were carried out in triplicate.
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Page 3 of 18Figure 2 Focused array analysis. The effect of 4 immunomodulatory herbal derivatives on LPS-induced THP-1 cells. (A) Heat map
representation of the expression profiles of 191 immune-related genes in THP-1 cells after the indicated treatments. Note the overall similarity
between Echinacea BF/S+L/Ep and cytopiloyne treatments. (B) Time profile of test compound effects on LPS-stimulated gene expression
compared to LPS stimulation only. (C) Correlation between gene expression patterns obtained from RT-PCR (left column) and focused array
(right column). Kinetics of the expression of TNF-a, IL-1b, and IL-8 genes were analyzed by RT-PCR and microarray. Red: LPS only; green: shikonin
+ LPS; black: emodin + LPS; blue: cytopiloyne + LPS; yellow: BF/S+L/Ep + LPS. The RT-PCR ratio was relative to the gene expression in vehicle
alone at the same time point. The Y-axis in the focused array is shown in log2 scale.
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Page 4 of 18Table 1 Genes down-regulated ≥3-fold by shikonin or emodin at 0.5 hours
Gene Expression Ratio (Test + LPS): LPS only
Gene Symbol Gene ID shikonin emodin cytopiloyne BF/S+L/Ep
Cytokines IL1B 3553 0.32 0.35 0.59 0.59
IL4 3565 0.25 0.2 0.92 0.81
IL13 3596 0.36 0.33 0.6 0.71
IRF1 3659 0.23 0.36 1.52 0.7
KITLG 4254 0.31 0.34 1.03 0.74
TNF 7124 0.24 0.68 0.38 0.85
TNFSF9 8744 0.34 0.32 0.62 0.8
Chemotaxis & Cell Migration CDH12 1010 0.22 0.34 0.23 0.45
CCR2 1231 0.24 0.17 0.82 0.88
CCR3 1232 0.26 0.38 0.49 0.55
CCR4 1233 0.29 0.35 1.01 0.86
CCBP2 1238 0.28 0.48 0.44 0.56
ICAM2 3384 0.29 0.28 0.73 0.79
ITGAE 3682 0.34 0.32 0.55 0.59
CCL4 6351 0.3 0.64 0.49 0.87
CCL8 6355 0.33 0.35 1.03 0.81
CCL22 6367 0.27 0.28 0.72 0.64
SELL 6402 0.26 0.91 0.58 1.15
SELP 6403 0.24 0.18 0.44 0.57
CXCR4 7852 0.39 0.19 0.59 1.26
CD207 50489 0.26 0.41 0.6 0.67
CLEC4A 50856 0.49 0.33 0.68 0.89
CLEC1A 51267 0.3 0.47 0.32 0.54
Inflammatory Responses CD1D 912 0.36 0.18 0.52 0.91
CD80 941 0.31 0.39 0.33 0.52
CSF3R 1441 0.49 0.33 0.69 0.82
IL2RA 3559 0.25 0.23 0.95 0.86
IL8RB 3579 0.27 0.34 0.64 0.53
LIFR 3977 0.27 0.48 0.32 0.6
MAP3K3 4215 0.3 0.27 0.78 0.73
NFATC3 4775 0.18 0.06 0.8 1.15
MAPK7 5598 0.28 0.26 1.09 0.66
PTGS1 5742 0.36 0.3 0.72 0.82
PTGS2 5743 0.25 0.17 1.03 0.93
SLAMF1 6504 0.33 0.58 0.37 0.67
STAT1 6772 0.29 0.2 1.04 0.8
LILRB4 11006 0.18 0.16 0.94 0.78
Other BCL2 596 0.32 0.4 0.7 0.65
BCL2L1 598 0.31 0.31 0.98 0.61
ETS1 2113 0.35 0.17 0.91 0.84
FUT7 2529 0.35 0.32 0.78 0.57
NR3C2 4306 0.33 0.48 0.89 0.66
NGFR 4804 0.32 0.34 0.73 0.68
TAP2 6891 0.2 0.14 0.72 0.85
TFRC 7037 0.29 0.37 1.01 0.72
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representations of the gene expression profiles in the
focused array, BF/S+L/Ep treatment and cytopiloyne
treatment shared a strikingly similar pattern (Figure 2A,
2B). We thus used RT-PCR analysis of three important
inflammatory response signature genes, TNF-a,I L - 8
and IL-1b, to confirm the data obtained from the micro-
array analyses, and found gene expression patterns simi-
lar to those observed in focused arrays (Figure 2C).
Taken together, these results (Figure 2B, 2C) lead us to
suggest that the data from our microarray assays repre-
sented meaningful gene expression patterns that can be
verified by independent gene expression assay systems.
Next, we clustered the genes into regulation modes
according to the four different patterns of changes in
their expression ratios observed after cytopiloyne treat-
ment following LPS stimulation. As stated previously, a
predominant trend of up-regulation was observed at the
4 h time point. Nevertheless, the early down-regulation
response of many of the genes allowed us to cluster the
majority of the genes into 3 distinct groups of regulation
mode, namely “early down-regulation followed by up-
regulation” (Figure 3A), “early non-response followed by
up-regulation” (Figure 3B), and “delayed down-regula-
tion followed by up-regulation” (data not shown). Indivi-
dual genes that did not fit into any of these three modes
were grouped into a fourth classification, “other” (data
not shown). We then compared the gene expression
patterns seen after cytopiloyne treatment with the gene
expression patterns seen after the other three treatments
and calculated the degree of similarity as the percentage
of genes that fell into the same regulation mode as cyto-
piloyne (Figure 3A, 3B). With BF/S+L/Ep treatment, the
majority of the genes in the “early non-response” group
(73.9%) and “early down-regulation” group (63.9%) fell
into the same regulation mode as cytopiloyne. With shi-
konin and emodin, the fractions of genes with regulation
modes corresponding to cytopiloyne were much lower:
“early non-response” group, 4.3% and 8.7%, respectively;
and “early down-regulation” group, 7.2% and 18.9%,
respectively (Figure 3A, 3B). In the “delayed down”
group, only 3.4%, 3.4%, and 24.1% of the genes affected
in the BF/S+L/Ep, shikonin, and emodin treatments,
respectively, displayed the same regulation mode as
cytopiloyne (data not shown).
We were curious about the detailed mechanism
responsible for the similarity in the effects of BF/S+L/Ep
and cytopiloyne. For this purpose, we compared the
expression profiles of the genes sharing common regula-
tion modes in both BF/S+L/Ep and cytopiloyne treat-
ment. Genes that displayed “early down-regulation”
modes were subsequently classified into 2 types of
expression profiles (Figure 4A, “up” and “down”) accord-
ing to the initial response of the gene in comparison
with LPS treatment in THP-1 cells alone. Strikingly, all
genes in the up-regulation sub-group showed sustained
up-regulation after both cytopiloyne and BF/S+L/Ep
treatments (Figure 4A, top panel). Genes that were
down-regulated by LPS-only treatment produced the
typical up-regulation pattern at 4 h with the Asteraceae
preparations (cytopiloyne a n dB F / S + L / E p )( F i g u r e4 A ,
lower panel). The same scenario was observed in
Table 2 Genes up-regulated ≥3-fold by BF/S+L/Ep or cyotpiloyne at 4 hours
Gene Expresion Ratio (Test + LPS): LPS only
Gene Symbol Gene ID shikonin emodin cytopiloyne BF/S+L/Ep
Cytokines CSF1 1435 0.91 1.69 3.54 3.12
IL5 3567 0.87 1.35 2.77 3.01
TNFSF14 8740 1.01 1.36 2.67 3.03
Chemotaxis & Cell Migration CCR1 1230 0.87 1.3 2.91 3.09
CCR8 1237 0.78 1.48 2.76 3.14
ITGAX 3687 1.08 1.38 2.88 3.19
CXCR4 7852 1.21 1.63 3.33 2.63
MADCAM1 8174 0.82 1.45 3.04 3.39
Inflammatory Responses CD14 929 0.9 1.56 3.24 3.26
MAP2K4 6416 1.25 1.4 2.59 3.56
TLR3 7098 0.91 1.33 2.35 3.06
IL1R2 7850 0.91 1.49 2.64 3.13
TNFRSF10D 8793 0.84 1.4 2.86 3.28
TBX21 30009 0.66 1.34 2.89 3.2
Other SHC1 6464 0.89 1.22 2.4 3.2
ADAMDEC1 27299 1.14 1.79 2.71 3
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mode (Figure 4B, lower panel).
Signaling molecules and associated pathways that may
be involved in the modulation of LPS-induced
inflammatory response
To find out the possible signaling pathways involved in
the different gene expression patterns observed in cyto-
piloyne, BF/S+L/Ep, shikonin and emodin treatments,
we analyzed the microarray data using the TRANS-
PATH database [21]. First, we analyzed those genes
whose expression was up- or down-regulated more than
threefold after 2, 4, and 12 h of LPS-only treatment to
verify the processing steps in the TRANSPATH data-
base. Three key molecules and signaling pathways were
observed: CKII (casein kinase II), JNK/JIP and p300
were the target molecules at 2, 4 and 12 h time points
respectively (Figure 5A). In this light, we reasoned that a
possible target for Asteraceae preparations could be a
common signaling molecule upstream of the genes shar-
ing same expression modes. We then subjected selected
genes from two groups (Figure 3A,3B) to key node ana-
lysis, which identified the ERK1/2 pathway as a single
common denominator at no more than 4 steps of hier-
archical gene regulation at 4 h (Figure 5B).
The shikonin- and emodin-affected genes were ana-
lyzed by the same method, an das p e c i f i cm o l e c u l ea n d
signaling pathway was observed for each treatment. The
possible master regulator in the treatment with shikonin
plus LPS at 0.5 h was identified by a signaling database
search as Rad23A (Figure 6A). The possible master regu-
lator in the emodin plus LPS treatment at 0.5 h was the
Table 3 Genes down regulated ≥3-fold by BF/S+L/Ep or cyotpiloyne at 12 hours
Gene Expresion Ratio (Test + LPS): LPS only
Gene Symbol Gene ID shikonin emodin cytopiloyne BF/S+L/Ep
Cytokines IL4 3565 1.12 0.94 0.68 0.25
IRF1 3659 2.01 0.87 0.78 0.27
TNFRSF11B 4982 0.93 0.81 0.66 0.26
TNFRSF10C 8794 1.04 0.96 0.86 0.32
Chemotaxis & Cell Migration CDH1 999 1.07 0.81 0.74 0.27
CDH12 1010 0.6 0.49 0.53 0.17
CCR2 1231 1.24 1.17 0.45 0.28
CCR3 1232 1.06 0.68 0.57 0.25
CCBP2 1238 0.98 0.83 0.69 0.22
ITGA2 3673 0.96 0.77 0.69 0.28
ITGB1 3688 0.9 1.69 0.72 0.32
CCL2 6347 0.7 0.7 0.29 0.7
CXCR4 7852 1.04 1.69 0.6 0.32
Inflammatory Responses CD80 941 1.71 1.09 0.55 0.3
GATA3 2625 1.15 0.88 0.72 0.26
IL7R 3575 1.67 0.88 0.73 0.3
IL8RB 3579 0.83 0.64 0.62 0.26
ITK 3702 1.07 0.95 0.79 0.3
LIFR 3977 1 0.84 0.74 0.27
NFATC3 4775 2.07 3.11 0.67 0.32
MAP2K5 5607 1.31 1.03 0.65 0.33
PTGS2 5743 1.26 0.97 0.63 0.29
SLAMF1 6504 1.04 0.74 0.59 0.3
IGSF6 10261 0.58 0.87 0.33 0.67
NFATC2IP 84901 1.1 0.78 0.66 0.22
Other ANXA3 306 0.97 0.88 0.65 0.33
BCL2 596 1.05 1.19 0.87 0.29
MPO 4353 0.84 0.77 0.68 0.27
C1orf61 10485 1.19 1.02 0.7 0.31
CLEC1A 51267 0.8 0.69 0.6 0.25
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treatment with cytopiloyne or BF/S+L/Ep, there was little
or no significant change in gene expression at the early
stage. However, among all four phytocompounds tested,
only the BF/S+L/Ep treatment showed a significant inhi-
bition of LPS-stimulated gene expression increase in our
focused array at 12 h (Table 3). Key node analysis of
genes with significant down-regulation pointed to E6-AP
as a possible master regulator (Figure 6C).
Having identified ERK1/2 as a putative target of both
BF/S+L/Ep and cytopiloyne (Figure 5B), we next aimed
to distinguish the mechanistic difference between these
two preparations. “Delayed down-regulation” was the
only group of genes with almost no intersection in
expression mode between BF/S+L/Ep and cytopiloyne
(data not shown). The genes in this group were again
analyzed using the TRANSPATH database, in search of
upstream effector molecules that were not present in
the other two expression modes (Figure 3A, 3B). This
analysis identified one potential pathway pointing to a
key regulator, Lck, a member of the Src family of pro-
tein tyrosine kinases important in T-lymphocyte activa-
tion and differentiation (Figure 7).
Delay in inactivation of the ERK pathway during the mid-
stage (~4 hours) of LPS stimulation
Since phosphorylation of ERK1/2 plays a pivotal role
during the activation of ERK signaling pathway [5,22],
we used western blot analysis to test our hypothesis that
ERK1/2 is a key molecular target for the actions of both
BF/S+L/Ep and cytopiloyne (Figure 5B). During LPS sti-
mulation in THP-1 cells, the phosphorylation level of
ERK1/2 molecules was first induced between 0.5 and
0.75 h post-treatment, it was then suppressed between 1
and 4 h post-treatment (Figure 8A, 8B). When LPS-sti-
mulated THP-1 cells were co-treated with test BF/S+L/
Ep (Figure 8A) or cytopiloyne (Figure 8B), a similar
trend of activation and suppression of phosphorylation
of ERK1/2 was observed, but the exact pattern and the
level of dephosphorylation of ERK1/2 in phytocom-
pound-treated cells were substantially different, resulting
in a delay in the dephosphorylation time course for
ERK1/2 in BF/S+L/Ep or cytopiloyne-treated cells. Den-
sitometer analyses showeda2 - 3f o l dc h a n g ei np h o s -
phorylated ERK1/2 levels for cytopiloyne and (BF/S+L/
Ep) between 1 and 4 h post-treatment.
Cascade network activities conferred by emodin and
BF/S+L/Ep (Figure 6B, C) were hypothesized to be
mediated by signaling or function via E6-AP, a key
member of the E3 ligase enzymes involved in ubiquiti-
nation pathways. We therefore also tested the ubiquiti-
nation activity in THP-1 cells treated with or without
these two test phytocompounds. By using a ubiquitin
enrichment assay to determine polyubiquitin levels of
total proteins in test cell samples, we were unable in
this case to detect a difference between phytocom-
pound-treated and untreated (control) cells (data not
shown). This result, however, has not ruled out the
Figure 3 Gene regulation patterns of phytocompounds clustered by different kinetics of expression ratio (compared to LPS
stimulation alone). The number of genes in each mode affected by cytopiloyne is shown above each left panel, while the percentage of these
genes with an expression regulation mode similar to the other three test compounds is shown above. (A) The cluster of “early down-regulation
followed by up-regulation”. (B) The cluster of “early non-response followed by up-regulation”. The Y-axis, in log2 scale, shows the ratio of gene
expression level between “LPS with compound treatment” and “LPS stimulation alone”.
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Page 8 of 18Figure 4 Sub-grouping the expression profile of the genes regulated in a similar mode by BF/S+L/Ep and cytopiloyne treatments. Two
patterns of LPS-induced kinetic gene expression were characterized into “Up” (first panel) and “Down” (second panel). The second and third
columns represent cytopiloyne or BF/S+L/Ep treatment, respectively. (A) Expression profiles of the genes corresponding to the “early down-
regulation” group in cytopiloyne treatment. (B) Expression profiles of the genes corresponding to the “early non-response” group.
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Page 9 of 18Figure 5 Candidate master switch molecules and signaling pathways involved in LPS-induced inflammatory response of monocyte
THP-1 cells. (A) Key node analysis was used to assess the possible signaling pathways or potential interactions in response to LPS stimulation
only, at different time points. Pink circle: the putative master regulator/molecule; red box: the up-regulation (≥ 3-fold) of gene expression
induced by LPS compared to vehicle treatment; green box: the down-regulation (≥ 3-fold) of gene expression induced by LPS compared to the
vehicle treatment; gray circle: assigned molecule in the putative pathway; ↑: activation; ⊥: inhibition. (B) TRANSPATH analysis of common
signaling denominators. Genes with the same expression mode in the “early non-response” and “early down-regulation” groups in both BF/S+L/
Ep and cytopiloyne treatments were analyzed. Only 4 hierarchical levels of regulation were accepted.
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Page 10 of 18Figure 6 Identification of putative signaling regulators for immune-modification. Key node analysis in the TRANSPATH database for
putative unique signaling master regulator/molecule at 0.5 h with significant inhibition of expression (≥3-fold decrease) in LPS-induced THP-1
cells co-treated with (A) shikonin, (B) emodin, or (C) BF/S+L/Ep at 12 h. Less than four hierarchical levels of regulation were accepted and
selected. Pink circle: the putative master regulator/molecule; green box: the ratio of gene expression seen with the phytocompounds plus LPS
compared to LPS only; gray circle: assigned molecule in the putative pathway; ↑: activation; ⊥: inhibition.
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affect ubiquitination activity in a specific manner via
E6-AP activity. Possible specific subset(s) of protein sub-
strates in test cells that may be affected in such a man-
ner by test phytocompounds will need to be evaluated
in future systematic studies.
Discussion
In this study, we characterized the immunomodulatory
pharmacogenomics of phytocompounds and herbal
extracts (shikonin, emodin, cytopiloyne and BF/S+L/
E p )o ng e n ee x p r e s s i o np r o f i l e si nL P S - i n d u c e dT H P - 1
cells, a well established immune cell line, using a tran-
scriptome approach. A number of key microarray
results obtained from LPS-only treatment were con-
firmed in this study by RT-PCR assay and pathway
analysis (Figure 2C, 5A). Our experimental results are
thus verified in general with overlapping and cross-
referencing in data for expression of several key test
genes. With this baseline information available, we
found that shikonin and emodin repress cytokine, che-
motaxis and cell migration genes through interference
with the ubiquitin pathway. BF/S+L/Ep and cytopiloyne
showed a striking similarity in their patterns of regula-
tion of immune-related gene expression, suggesting the
presence of compounds with similar activity to cytopi-
loyne in the Echinacea purpurea preparations. Hence,
co-treatment of THP-1 cells with LPS and shikonin,
emodin or other phytocompounds was designed here
to evaluate the very early response or even a preven-
tion/blockade activity of an inflammatory response, in
reaction to LPS, which serves as a common inflamma-
tory stimulator.
Using a structured network knowledge-based
approach to analyze genome-wide transcriptional
responses, Calvano recently reported that specific func-
tional modules, defined as typical innate immune activ-
ities, in human blood leukocytes are highly responsive
to inflammatory endotoxin stimulation in vivo. Our cur-
rent in vitro investigation into the transcriptional
response of a monocyte/macrophage cell system, using a
focused DNA microarray with a smaller subset of
immune-related genes, has found interesting similarities
in the effect of early and medium innate immune gene
expressions involved in the inflammatory response. As
an example, the expression of proinflammatory cyto-
kines and chemokines (TNF, IL-1 beta, CCL2 and IL-8)
reached a peak during the early (0.5 h) and medium
(4 h) stages of inflammatory response. Therefore, the
findings obtained in this study are complementary to
and consistent with the previous in vivo studies [23].
It has been shown that quiescent/inactive monocytes
or macrophages do not express IL2RA (the alpha chain
of IL-2 receptor); however, expression of IL2RA gene
has been shown to be inducible after activation of
human peripheral blood monocytes [24-26]. The mole-
cular mechanism for IL2RA gene regulation by M.
tuberculosis, a gram-negative bacterium, has been shown
to be mediated via activation of NF-B in THP-1 cells,
our test cells [27]. Therefore, it is possible that IL2RA
expression can occur in THP-1 cells. Nonetheless,
although we have shown in this study that IL2RA
mRNA expression is down-regulated in LPS-stimulated
THP-1 cells after treatment with shikonin or emodin,
the down-regulation does not necessarily correlate with
a decrease in protein levels of IL2RA in test cells treated
with phytocompounds, as post-transcriptional and post-
translational modifications, including regulation via
microRNAs and ubiquitin/proteosome pathways, are
well known to affect protein expression of a target
mRNA. An example is the effect of shikonin on TNF-a
gene expression, as we have previously shown in THP-1
Figure 7 Identification of putative common signaling
denominators shared by treatments with BF/S+L/Ep and
cytopiloyne. Key node analysis in TRANSPATH database for putative
unique signaling denominator of the “delayed down-regulated”
group between BF/S+L/Ep and cytopiloyne. Only four hierarchical
levels of regulation were accepted.
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possibility.
This relatively small-scale, function-targeted focused
DNA microarray set and the specific time course design,
when employed to distinguish the effect of different
phytocompounds/medicinal herbal extracts on the pat-
terns of kinetic gene expression, is hence a useful strat-
egy for analyzing the specific molecular mechanisms
involved in the bioactivities of various candidate herbal
medicines. Since the LPS-stimulated THP-1 cell system
is one of the most widely-used models for macrophage
activation, our findings on the differential effects of var-
ious phytocompounds on anti-inflammatory activities
may thus have a general application. In this study, we
have used THP-1 cells that were not treated with LPS
as an internal control. It is important to note here that
the response of THP-1 to LPS obtained in the present
study is in good agreement with various reports from
previous studies [3,15-17,23]. We then compared data
obtained in the set from treatment with LPS only with
the vehicle control set (i.e., without LPS treatment, data
not shown) and further analyzed the gene expression
patterns (Figure 2C) and the possible signaling pathways
or potential interactions involved (Figure 5A). The study
was hence designed as a pharmacogenomics approach
for evaluation and classification of various anti-inflam-
matory natural products, mainly phytochemicals with
reputed medicinal bioactivities, into potentially clinically
relevant or applicable subgroups.
Shikonin and emodin resulted in significant inhibition
(to less than 30% of control) of most of the inflamma-
tion responsive genes as early as 0.5 h after treatment
(Table 1). Shikonin has previously been shown to exhibit
anti-inflammatory activity [28], and here we also
observed shikonin suppression of the expression of a
number of immune-related genes, including TNF-a,
Figure 8 Delay in inactivation of the ERK pathway during the mid-stage of LPS stimulation. The phosphorylation levels of ERK1/2 were
determined by western blotting analysis after LPS-stimulated THP-1 cells were co-treated with (A) BF/S+L/Ep (Ep) or (B) cytopiloyne (CP).
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inhibit a group of genes that are associated with macro-
phage activation at the very early stage of inflammatory
response.
Following emodin treatment, approximately 30 genes
were significantly down-regulated even after 48 h (data
not shown). However, there was less emodin inhibition
of some chemotactic and cell migration gene expression,
such as CCBP2 and CCL4 compared to shikonin (Table
1). This suggests that emodin might down-regulate
inflammatory cytokines rather than immune cell recruit-
ment and cell migration. Recently, emodin has been
shown to exert an anti-inflammatory effect by inhibiting
NF-B activation and inflammatory cytokine expression
[10,11]. We suggest that both shikonin and emodin may
strongly inhibit macrophage activation, but that chemo-
taxis and the recruitment of T lymphocytes are less
affected by emodin. Further experiments are necessary
to confirm this possibility.
We analyzed possible signaling pathways and modula-
tors using key node analysis of those genes significantly
inhibited (≥3-fold) by shikonin and emodin treatments
(Figure 6A, B respectively) in LPS induced THP-1 cells
at the 0.5 h time point (Table 1). The pattern of down-
regulated gene expression seen with shikonin at 0.5 h
suggested an increase in expression of Rad23A, which
binds and delivers ubiquitinated proteins to the protea-
some, and subsequent inactivation of the p-300, tran-
scriptional co-activator protein. The down-regulated
LPS gene expression pattern following emodin suggested
that the activity of Ub protein ligase E6-AP may be
blocked at 0.5 h. These ubiquitination and de-ubiquiti-
nation mechanisms are emerging as important regula-
tors of Toll-like receptor (TLR) signaling. Recent
findings on TLR signaling pathways have shown that Ub
is a key molecule of the NF-B inhibitory proteins that
can prevent the formation of signaling complexes
[22,29,30]. Therefore, interfering with ubiquitination
activity may prove to be a useful strategy for developing
therapeutics targeting severe inflammatory diseases. We
show here that both shikonin and emodin may act as
immediate-early inhibitors of inflammation through
interfering with ubiquitin pathways, their use as anti-
inflammatory remedy may warrant future evaluation,
especially since we have shown that shikonin can be
very effective in vivo in wound-healing activities in skin
tissue [31].
Although BF/S+L/Ep did not inhibit the early macro-
phage-activation stage at 0.5 h, high suppression of gene
expression was however observed at 12 h (Figure 6C,
Table 3), which continued for up to 48 h (data not
shown). TRANSPATH database analysis suggested that
the level of ubiquitination of Rad23A regulated by Ub
protein ligase may be increased. This indicates that BF/S
+L/Ep may not have strong inhibitory activity in the
e a r l ys t a g eo ft h ei m m u n er e s p o n s ea n dm a yb em o r e
immunomodulatory than immunosuppressive.
On the other hand, although very few immune-related
genes were strongly affected by cytopiloyne and BF/S+L/
Ep, the gene expression pattern of these two treatments
displayed an obvious similarity. The resemblance
between BF/S+L/Ep and cytopiloyne treatments was
even more evident in analysis of the time profile of the
gene expression ratio compared to LPS stimulation,
which was characterized by an up-regulation of gene
expression after 4 h of stimulation (Figure 3A and 3B,
Table 2). Despite the overall similarity, cytopiloyne
showed some mechanistic differences contributing to
the delayed down-regulation of genes at 2 h, which was
not seen in the BF/S+L/Ep treatment.
To study the detailed mechanism responsible for the
similar effects of BF/S+L/Ep and cytopiloyne treatment,
we compared the expression profiles of those genes that
shared common regulation modes between the two
treatments. BF/S+L/Ep and cytopiloyne did not show
any significant differences in the “up” group, whereas
there were significant differences in the “down” group
(Figure 4A). The same scenario was observed with the
genes displaying the “early no-response followed by up-
regulation” mode (Figure 4B). This analysis further sup-
ports the idea that both Asteraceae preparations may
affect common master regulator(s) to modulate the
expression of immune genes, which are up-regulated at
4 h, and alleviate the down-regulation of genes inhibited
by LPS stimulation.
We then analyzed these groups of genes using the
TRANSPATH database, which identified the ERK1/2
pathway as a common key regulator at no more than 4
hierarchical levels of gene regulation (Figure 5B). We con-
firmed that the ERK1/2 pathway was a regulator by wes-
tern blot analysis experiments (Figure 8A, B) that showed
a delay in inactivation of ERK1/2 activities in THP-1 cells
when they were treated with BF/S+L/Ep or cytopiloyne.
ERK1/2 activation has long been recognized as a pivotal
regulation in macrophage activation and cytokine expres-
sion during inflammatory responses [32,33]. ERK1/2 mole-
cules are phosphorylated on the threonine and tyrosine
residues within minutes of TLR-4 stimulation of macro-
phages and dendritic cells, as shown via treatment with
LPS [34,35]. Our data showing retarded dephosphorylation
of ERK1/2 between 2 and 4 h may help to explain the up-
regulation of several groups of gene expression at 4 h
(Table 2) when test cells were treated with BF/S+L/Ep or
cytopiloyne. Recent studies have shown that inactivation
of MAPK occurs primarily through regulation via depho-
sphorylation. The mitogen-activated protein kinase phos-
phatase (MKP) family includes serine-threonine
phosphatases (PP2A and PP2C), protein tyrosine
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Page 14 of 18phosphatases (PTPN5, PTPN7, and PTPRR) [36,37], and
members of the dual-specificity phosphatases (DUSP)
family [35]. There is considerable evidence from both ani-
mal model and human studies that pharmacological inhi-
bition of ERK activation may help modify inflammatory
responses for clinical applications [34]. Since our data sug-
gest that cytopiloyne and BF/S+L/Ep can effectively inter-
fere with the dephosphorylation status of ERK1/2, the
DUSPs may thus represent one of the most likely candi-
dates for such activity.
This study and our previous reports [9,13,14,20] have
shown that some Asteraceae plant preparations have
very desirable pharmacological properties, including low
cell toxicity, anti-inflammatory bio-activity, and a high
specific index. Therefore, the current finding on the
mechanistic explanation of the Asteraceae preparations
action on ERK regulation warrants further investigation.
Interestingly, cytopiloyne also possesses the unique abil-
ity to delay the suppression of genes downstream of the
Lck pathway (Figure 7). The LPS-induced NF-Bp a t h -
way depends on phosphorylation of IB-b, and Src tyro-
sine kinases such as cSrc and Lck, which are key
components of the LPS signaling pathway [4,7]. This
suggests that cytopiloyne might affect NF-B activation
through interference with Lck.
Conclusions
We used a functional genomics approach to characterize
and compare the mechanisms and kinetics of immune
modulation of LPS-stimulated THP-1 cells by a range of
anti-inflammatory phytocompounds, including shikonin,
emodin, Echinacea extract and cytopiloyne. Shikonin
and emodin exhibit immediate early inhibitory activities,
apparently by interfering with the ubiquitin pathway.
Comparative analysis further showed that BF/S+L/Ep
and cytopiloyne shared a similar mode of modulation of
immune-related gene expression during acute inflamma-
tion, and mode-clustering analysis suggested that the
ERK1/2 activation pathway was the target of both cyto-
piloyne and BF/S+L/Ep. These findings may suggest the
presence of active compound(s) related to cytopiloyne in
Echinacea purpurea preparations [20], and offer
mechanistic insight for possible development of these
phytocompounds as defined therapeutic agents. We also
suggest that specific and structurally different phyto-
compounds/extracts may exert their immune modula-
tory effects through recruitment of a number of
common signaling networks of immune-responsive
genes that warrant future systematic investigation.
Methods
Cell culture and monocyte preparation
The human myelogenic leukemia cell line THP-1 was
purchased from American Type Culture Collection
(Rockville, MD). Cell cultures were maintained in RPMI
1640 (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum (Life Technologies, Rockville, MD),
penicillin (100 U/ml) (Life Technologies), and strepto-
mycin (100 μg/ml) (Life Technologies) at 37°C in 5%
CO2 in a humidified incubator.
Preparation of phytocompounds
Shikonin was purchased from TCI (Tokyo, Japan), emo-
din was purchased from Acros Organics (Morris Plains,
NJ), and cytopiloyne was isolated as described previously
[12] and provided by the Metabolomics Core Laboratory
of the Agricultural Biotechnology Research Center, Aca-
demic Sinica.
Cell viability assay
Cell viability was assayed by MTT colorimetric dye
reduction method as described previously [14]. Extracts
or phytocompounds tested were serially diluted: shiko-
nin (0.1, 0.5, 1 and 10 μM); emodin (1, 10, 50 and 100
μM); cytopiloyne (1, 10, 50 and 100 μM); BF/S+L/Ep (1,
10, 100, and 200 μg/ml). Throughout our experiments,
LPS was used at 1 μg/ml in test culture medium for sti-
mulation of THP-1 cells.
RNA isolation
1×1 0
7 THP-1 cells were transferred to a 10 cm Petri
dish in 10 ml culture medium. After incubation over-
night, test phytocompounds and LPS were added, and
cells were then harvested at different time points. THP-1
cells were collected and pelleted in a microcentrifuge at
900 rpm, and the culture medium supernatant removed.
Pelleted THP-1 cells were lyzed with Trizol reagent and
extracted with chloroform. The upper aqueous phase was
collected by centrifugation at 4°C, 14000 rpm for 15 min-
utes, and RNA was precipitated from solution by the
addition of an equal volume of isopropanol. RNA pellets
were washed twice with 75% ethanol/DEPC, and dis-
solved in DEPC-treated water. Concentration and quality
of the RNA samples was analyzed by absorbance at 260/
280 nm, before they were stored at -80°C.
RNA electrophoresis
Aliquots of 2 μl RNA sample (5 μgt o t a lR N A )w e r e
added to 10 μl of a glyoxal reaction mixture in a closed
microcentrifuge tube, incubated at 55°C for 1 hour and
then chilled on ice for 2 min, when the aqueous dro-
plets condensed on the wall of the microcentrifuge tube
were spun down. RNA samples made up in 1× BTPE
buffer (10 mM PIPES, 30 mM Bis-Tris, 0.1 mM EDTA,
pH 6.5) were loaded onto a 6 cm-long 1% agarose gel,
and electrophoresed in 1× BTPE buffer at 100 V for 15
minutes. Gels were photographed without additional
staining.
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DNA primers used to investigate the effect of phyto-
compounds on the expression of TNF-a, IL-1b and IL-8
RNA contained the following sequences: Human TNF-a
sense primer: 5′-CAGGCAGTCAGATCATCTTCTC-
GAAC-3′.H u m a nT N F - a anti-sense primer: 5′-
CGTTTGGGAAGGTTGGATGTTCGTCC-3′.H u m a n
IL-1b sense primer: 5′-CCCCAGCCCTTTTGTTGA-3′.
Human IL-1b anti-sense primer: 5′-TTCTTGCCC-
CCTTTGAATAAATT-3′. Human IL-8 sense primer: 5′-
CTTGGCAGCCTTCCTGATTT-3′.H u m a nI L - 8a n t i -
sense primer: 5′-CTCAGCCCTCTTCAAAAACT-3′.
Human GAPDH sense primer: 5′-GAAGGTGAAGGT-
CGGAGTC-3′. Human GAPDH anti-sense primer: 5′-
GAAGATGGTGATGGGATTTC-3′. RT-PCR reactions
used the AccessQuick RT-PCR system (Promega U.S.,
Madison, WI) according to the manufacturer’si n s t r u c -
tions. Briefly, 1 μg of total RNA from each sample was
added to the reaction mixture containing 1× Access-
Quick master mix (Tfl DNA polymerase, AMV/Tfl reac-
tion buffer, 25 mM MgSO4 and 10 mM dNTP mixture),
10 μM each of specific sense and anti-sense primers, 5U
AMV reverse transcriptase, and nuclease-free water to a
final volume of 50 μl. Reactions were incubated at 48°C
for 60 min, and PCR amplification was carried out after
denaturing at 95°C for 2 min. Images were scanned and
densitometer analysis of the captured image was per-
formed with BIO-1 D image analysis software. The sig-
nal intensities of test genes in different samples were
normalized to the respective mouse GAPDH signal
intensity.
DNA microarray
The focused, immune function-targeted DNA microar-
ray system was constructed using synthesized oligonu-
cleotide probes as described in our previous study [14].
Briefly, 228 immune function-associated genes were
selected and grouped into specific cellular immunologi-
cal functions, such as chemotaxis, antigen processing,
maturation and signaling in dendritic cells, apoptosis,
and other immune-related activities. A number of non-
immune related, functional genes (e.g., metabolism), and
housekeeping genes were also included. Oligonucleotide
probes were designed and synthesized with a length of
approximately 50 nucleotides to represent specifically
these genes as defined by the U-GET program as
reported by Iyer et al. [38] and our previous studies
[14,39]. This gene list is now freely available to the pub-
lic scientific community upon request (Additional file 1:
Table S1). A two color CyDye system was used for
determining the ratio of gene expression for test/control
set sample after different treatments.
Reverse transcription and first strand cDNA labeling with
amino allyl-dUTP (AA-dUTP)
At o t a lR N As a m p l e( 2 0μg) was mixed with 3 μlo f
Oligo dT primer (Amersham Pharmacia Biotech, Buck-
inghamshire, UK) and heated at 70°C for 5 minutes,
then allowed to cool for 10 minutes at room tempera-
ture. The reaction mixture (total volume 20 μl), contain-
ing 4 μl of 5X first-strand buffer, 2 μl of 0.1 M DTT, 1
μl of a 20X nucleotide mixture, 1 μl AA-dUTP and 1 μl
of reverse transcription reaction, was incubated at 42°C
for 1.5 h. The reaction was terminated by addition of 2
μl of 2.5 M NaOH and followed by incubation at 37°C
for 15 min. The reaction mixture was neutralized with
10 μl of 2 M HEPES and the synthesized cDNA product
was cleaned up with a Microcon purification kit (Milli-
pore, YM30). The cDNA pellet was then speed-vacuum
dried and resuspended in 15 μl water.
Labeling of amino allyl-modified cDNA with CyDye
An aliquot of CyDye (Cy3 or Cy5, GE Healthcare) was
resuspended in 15 μlf r e s h0 . 1MN a H C O 3 pH 9.0,
immediately prior to use in a labeling reaction. One ali-
quot of resuspended CyDye was then added to one tube
of AA-dUTP-modified cDNA (see above) using Cy3 for
control samples, and Cy5 for treated samples. Tubes
were mixed by stirring, and incubated at room tempera-
ture in the dark for 1 hour, after which 15 μl 4-hydroxy-
lamine was added to each coupling reaction, mixed well
and incubated at room temperature in the dark, for a
further 15 minutes. CyDye-labeled cDNA was then puri-
fied using a DNA purification kit (Qiagen). The allyl-
modified cDNA pellet was then speed-vacuum dried
and resuspended in 5 μl water.
Hybridization
A probe was prepared in fresh hybridization solution
consisting of 30% formamide, 5X SSC, 0.1% SDS, and
0.1 mg/ml of a nucleic acid blocker, human Cot1 DNA.
The probe was incubated in solution at 95°C for 5 min-
utes, then lightly centrifuged for 2 minutes to collect
condensation, and cooled to room temperature for 20
m i n u t e s ,a n dp l a c e di nah y b r idization chamber (Corn-
ing, cat. No.2551). The probe was then pipetted onto
the printed surface of the slide. A coverslip was carefully
placed on top of the array to avoid bubble formation
during hybridization. The chamber was placed in a 42°C
water bath for 16 hours.
Post-hybridization washing
The array was washed in 2× SSC, 0.1% SDS at 42°C for
5 minutes, and then in a second buffer containing 0.1×
SSC, 0.1% SDS at room temperature for 5 minutes, and
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washed 4 times in 0.1× SSC buffer at room temperature
for 1 minute. The array was then dried by centrifugation
(800 rpm, 10 min), and the signal emitted from each
spot was analyzed with digital imaging software (Gene-
pix 4.0, Axon Instruments, MDS Analytical, Toronto
Canada).
Western blot analysis
Total proteins were extracted from test THP-1 cells
with ice-cold lysis buffer (150 mM NaCl, 0.5% Triton X-
100, 50 mM Tris-HCl (pH 7.4), 20 mM EGTA, 1 mM
dithiothreitol (DTT), and protease inhibitor cocktail)
and centrifuged at 12,000 × g for 20 min. Protein sam-
ples were subjected to western blotting as described pre-
viously.
9 Briefly, test proteins were assayed after
overnight incubation at 4°C with 1:1000 dilution of poly-
clonal p44/p42 MAPK (ERK1/2) or phosphor-specific
ERK1/2 antibodies (Cell Signaling). Equal protein load-
ing was assessed using mouse a-actin (Sigma Chemical
C o . ,S t .L o u i s ,M O ) .T h ep r o t e i n sw e r ev i s u a l i z e dw i t h
an enhanced chemiluminescence (ECL) detection kit
(Amersham).
Data and signaling pathways analysis
T h ef o c u s e da r r a ys y s t e mt h a tw eu s e di nt h i ss t u d y
was adapted from the system reported by Iyer et al.
[38] and Wang et al. [14]. We employed Cy3 and Cy5
fluorescent dyes to label the RNA samples obtained
from the control and treatment groups, respectively.
The Cy3 (control) and Cy5 (test) labeled RNA samples
were then mixed and subjected to hybrdization with
oligo-nucleotide probes on chips. Five different house-
keeping genes, alpha-Tubulin (NM_006082), beta-2-
microglobulin (NM_004048), beta-actin (NM_001101),
GAPDH (NM_002046), Transferrin R (NM_003234),
have been built into the design of our “array genes”.
These 5 housekeeping genes were hence employed as
the “internal controls” of our gene chip assay. Within
each array chip, four replicates for each gene were
used.
The scanning output generated from the focused
arrays was fed into GenePix to extract numerical
expression readings from each spot. The relative
expression level of each gene was represented by the
median of ratio (Cy5/Cy3) averaged from the four
replicates of a gene on the same array. As we pre-
viously described [14], our microarray data were ana-
lyzed using the Spotfire software, which includes
established algorithms that determine whether a gene
is present or absent and whether the expression level
of a gene in specific experimental test samples is sig-
nificantly increased or decreased (≥ 3-fold change)
relative to a control sample, and for clustering distinct
groups of gene expression profiles (hierarchical cluster-
ing and K-means). The signals obtained from different
chips (test sets) were normalized by the relative
expression level (in ratio) to the b-actin (B2M) gene.
Only those genes that showed at least a 3-fold change
in expression level after phytocompound or extract
treatment were listed in our study and then further
classified into different gene cluster groups and used
for analyses of signaling networks [40]. Other measures
for data processing, information search and analyses,
such as the use of KEGG (Kyoto Encyclopedia of
Genes and Genomics; http://www.genome.jp/kegg/ and
TRANSPATH, have been briefly described previously
[14,20]. The TRANSPATH database offers good details
on molecules or networks of the signaling flow from
the cell membrane into the nucleus, focusing on mam-
mals such as humans, mice, and rats [21].
Additional material
Additional file 1: 228 gene list with ontological description. The list
was represented gene IDs, symbols and names of 228 genes with
ontological description in our DNA microarray system.
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